PDCD1 and neoplasm: Our current study provides a new mechanistic understanding to accentuate the significance of co-targeting tumor-derived soluble NKG2D ligand, sMIC, to enhance the therapeutic efficacy of PD1/PDL1 checkpoint blockade therapy for melanoma patients.